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Deep vein thrombosis and pulmonary embolism are major health
problems associated with high mortality. Recently, DNA-based
neutrophil extracellular traps (NETs) resulting from the release of
decondensed chromatin, were found to be part of the thrombus
scaffold and to promote coagulation. However, the signiﬁcance
of nuclear decondensation and NET generation in thrombosis is
largely unknown. To address this, we adopted a stenosis model of
deep vein thrombosis and analyzed venous thrombi in peptidy-
larginine deiminase 4 (PAD4)-deﬁcient mice that cannot citrulli-
nate histones, a process required for chromatin decondensation
and NET formation. Intriguingly, less than 10% of PAD4−/− mice
produced a thrombus 48 h after inferior vena cava stenosis
whereas 90% of wild-type mice did. Neutrophils were abundantly
present in thrombi formed in both groups, whereas extracellular
citrullinated histones were seen only in thrombi from wild-type
mice. Bone marrow chimera experiments indicated that PAD4 in
hematopoietic cells was the source of the prothrombotic effect in
deep vein thrombosis. Thrombosis could be rescued by infusion of
wild-type neutrophils, suggesting that neutrophil PAD4 was im-
portant and sufﬁcient. Endothelial activation and platelet aggre-
gation were normal in PAD4−/− mice, as was hemostatic potential
determined by bleeding time and platelet plug formation after
venous injury. Our results show that PAD4-mediated chromatin
decondensation in the neutrophil is crucial for pathological venous
thrombosis and present neutrophil activation and PAD4 as poten-
tial drug targets for deep vein thrombosis.
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Venous thromboembolism is associated with high mortality,with ∼300,000 deaths resulting from an estimated 900,000
cases in the United States annually (1). Neutrophil extracellular
traps (NETs) are produced by a cell death pathway shown to be
important in innate immunity against microbes (2–5). Recently,
NETs were also shown to be involved in thrombosis by binding
erythrocytes and platelets (6) and in promoting coagulation
by degrading tissue factor pathway inhibitor (7). Coagulation,
platelets, neutrophils, and NETs have all been implicated in
thrombus generation in mouse models of deep vein thrombosis
(DVT) (8–10). Also, certain cancers associated with neutrophilia
result in an increased propensity of circulating neutrophils to
form NETs and spontaneous thrombosis (11). NETs are com-
posed of decondensed chromatin ﬁbers lined with antimicrobial
proteins such as neutrophil elastase and myeloperoxidase (2).
A proteomic analysis identiﬁed histones as the major protein
component of NETs (12). Histones are highly cytotoxic to the
surrounding environment into which NETs are released (13, 14)
and can enhance thrombin generation (15). Histone infusion
leads to rapid Weibel–Palade body (WPB) secretion from en-
dothelial cells, promoting platelet and leukocyte adhesion and
leading to accelerated thrombus generation (9). Pretreatment
with DNase 1, which can degrade NETs, reduces thrombus in-
cidence in wild-type (WT) mice (9, 10). Neutrophils play an im-
portant role, as neutrophil depletion greatly reduces thrombus
weight in this model (10). Whether NETs are involved in the
pathogenesis of DVT or whether they are merely a consequence
of leukocyte recruitment to the thrombus is unknown. Similarly,
the role of NETs in normal platelet plug formation in response to
injury, where their presence was also observed (7), remains to
be addressed.
Although the cellular changes occurring in the neutrophil during
the process of generating neutrophil extracellular traps (NETosis)
have been well described, the molecular players and processes
leading to NET formation are incompletely deﬁned. A critical step
in NET formation is the decondensation of chromatin that occurs
in the nucleus. Peptidylarginine deiminase 4 (PAD4) is a nuclear
enzyme that converts speciﬁc arginine residues to citrulline on
histone tails. Upon PAD4 activation, histones can become hyper-
citrullinated at histone H3Arg-8 and -17 or at histone H4Arg3
residues, resulting in the extensive chromatin decondensation that
leads to nuclear delobulation and swelling during NETosis (16,
17). PAD4-deﬁcient mice are incapable of decondensing
chromatin or forming NETs (18), whereas overexpression of
PAD4 is sufﬁcient to drive chromatin decondensation to form
NET-like structures in cells that normally do not form NETs (19).
Because NETs are present in pathological thrombi and their dis-
solution by DNase 1 reduced the frequency of DVT, it was im-
portant to address the role of histone modiﬁcation by PAD4 in the
process of NET formation and its involvement in thrombosis.
Results
PAD4−/− Neutrophils Fail to Produce NETs in Response to
Lipopolysaccharide or Ionomycin. PAD4 is a calcium-dependent
enzyme with a nuclear localization signal that distinguishes it
from other PAD family members (20, 21). The enzyme is acti-
vated by Ca2+ (17), and therefore the calcium ionophore ion-
omycin was used to induce histone hypercitrullination in isolated
peripheral blood murine neutrophils (Fig. 1A). This led to NET
formation in WT and PAD4+/− neutrophils, whereas PAD4−/−
neutrophils did not citrullinate histone H3 or form NETs (Fig. 1
A and B). Lipopolysaccharide (LPS) from Klebsiella pneumoniae
was also unable to induce histone citrullination or NETs in
PAD4−/− neutrophils, whereas it is a potent inducer of NETosis in
WT neutrophils (Fig. 1 A and B). Moreover, immunostaining
showed citrullinated histone H3 (H3Cit)-positive NETs being
released from WT neutrophils, whereas in PAD4−/− neutrophils
H3Cit staining was absent (Fig. 1C). Although PAD4−/− nuclei
lost their lobulated shape characteristic of neutrophils, they did
not swell, indicating that nuclear decondensation is not occurring
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in PAD4−/− mice and conﬁrming that other PAD enzymes do not
compensate for PAD4 deﬁciency in vitro. Ionomycin-induced
NETosis has been shown to be independent of reactive oxygen
species (22), and here we show that it is dependent on PAD4.
Thus, PAD4−/− neutrophils have shown a complete inability to
produce NETs (18) (Fig. 1B).
PAD4−/− Mice Are Protected in the Venous Stenosis Model of DVT.
Biomarkers of NETs are abundant in baboon (6) and mouse
DVT (9). We performed the venous stenosis model of DVT in
mice (8). Brieﬂy, the inferior vena cava (IVC) is ligated to induce
a 90% restriction in blood ﬂow. This results in the formation of
a thrombus that is macroscopically similar to human deep vein
thrombi. It contains a platelet-rich white portion (distal to the
ligation site) and an erythrocyte-rich red portion (proximal to the
ligation site). Because PAD4-deﬁcient mice do not form NETs
in vitro, we hypothesized that NET formation would be greatly
impaired in these mice during thrombosis and that this may af-
fect thrombus formation and/or stability. PAD4−/− mice were
partially protected from producing venous thrombi early after
stenosis, with only 28.6% of PAD4−/− mice forming thrombi at
6 h compared with 66.7% of WT mice (P = 0.04) (Fig. 2A).
Thrombi that formed in PAD4−/− mice were similar in length to
WT thrombi (Fig. 2B). PAD4−/− mice also maintained normal
platelet counts compared with control sham-operated animals
and after stenosis had signiﬁcantly higher platelet counts than
WT mice (Fig. 2C). In contrast to the diffuse extracellular H3Cit
pattern in thrombi previously described at 48 h (9), immunos-
taining revealed that the majority of H3Cit was nuclear rather
than extracellular in the WT thrombi at this early time point
(Fig. S1A), whereas H3Cit staining was not detected in PAD4−/−
thrombi (Fig. S1B) (WT, 28.3 ± 0.75 H3Cit+ cells per mm2;
PAD4−/−, no H3Cit+ cells detected; n = 4). The thrombi pre-
sented similar histological morphologies with comparable den-
sity of leukocytes as seen by H&E staining (Fig. S1C). To see if
this early protection could be a result of delayed thrombus for-
mation in PAD4−/− mice, we next maintained stenosis for 48 h,
when the great majority of WT mice form a thrombus (8), and
found that, whereas 90% of WT stenotic vessels thrombosed,
fewer than 10% of PAD4−/− mice had a thrombus at this time
point (P = 0.0002) (Fig. 2 D and E). Thrombocytopenia was
associated with thrombus formation in WT mice, whereas
PAD4−/− mice retained normal platelet levels (Fig. 2F). Thus,
platelets are likely consumed by the thrombus. It is important to
note that at baseline WT and PAD4−/− mice had similar platelet
counts (Fig. 2F). The extracellular H3Cit meshwork seen in WT
thrombi at 48 h postligation was again completely absent in the
sole PAD4−/− thrombus, indicating also that in vivo only PAD4
modiﬁes histone H3 to produce H3Cit (Fig. 2 G and H). He-
matoxylin and eosin staining revealed many swollen neutrophil
nuclei in WT thrombi, whereas the PAD4−/− thrombus contained
smaller and more dense neutrophil nuclei (Fig. 2I). Neutrophils
are abundantly present within WT thrombi at 48 h (9) and also in
the only thrombus in the PAD4−/− mouse (Fig. 2J), suggesting
that neutrophils are recruited to the PAD4−/− thrombus. NETs
were absent in the single small PAD4−/− thrombus that we
obtained and analyzed by immunoﬂuorescence staining. Thus,
PAD4 deﬁciency was highly protective in the DVT mouse model
at 48 h when, in WT mice, extracellular chromatin is prominently
displayed (9) (Fig. 2G).
Endothelial Activation and Platelet Function Are Not Affected by
PAD4 Deﬁciency. Although PAD4 is highly expressed in neu-
trophils, it is also present at lower levels in many cell types, where
citrullination of histones may regulate gene expression (17, 23).
Therefore, it was important to establish in which cell type PAD4
was responsible for this prominent role in pathological throm-
bosis. First, we wanted to investigate whether endothelial release
of adhesion molecules for platelets and leukocytes, von Wille-
brand factor (VWF) and P-selectin, from WPBs occurs normally
in PAD4−/− mice. Both VWF and P-selectin were determined to
be important in the stenosis model of DVT (8, 10). We turned to
a time point (6 h) by which WPBs have been released, resulting in
massive platelet and neutrophil adhesion to the endothelium (8).
Platelet/leukocyte adhesion and aggregate formation on the IVC
vessel wall were similarly present in both WT and PAD4−/− IVCs
6 h after stenosis (Fig. 3A) (WT, 8.97 ± 0.50; PAD4−/−, 13.56 ±
2.11 leukocytes per 200 μm of vessel wall; P = 0.10; n = 3).
Another way to examine the capacity of mice to release WPBs
is by infusion of activated platelets, which results in systemicWPB
release from endothelial cells and consequently increases leuko-
cyte rolling in veins (24). Leukocyte rolling occurred in both WT
and PAD4−/− mice to a similar extent over baseline 2 h after ac-
tivated platelet infusion (Fig. 3 B and C), an interaction that is
dependent on endothelial P-selectin and P-selectin glycoprotein
ligand-1 (PSGL-1) on leukocytes (24). Plasma VWF levels were
similarly elevated in WT and PAD4−/− mice 2 h after platelet
infusion (WT, 154.6 ± 8.24%; PAD4−/−, 140.0 ± 21.8% of control
pooled plasma; n = 4, P = 0.56). Taken together, the protection of
PAD4−/− mice in DVT is not due to a defect in endothelial activa-
tion leading to VWF and P-selectin release, nor is it due to a defect
in the initial leukocyte and platelet adhesion to the vessel wall
that is essential for thrombus initiation in venous stenosis (8, 10).
Because PAD4 could be expressed in megakaryocytes and thus
affect the properties of platelets, we next evaluated the platelets
from PAD4−/− mice. As Fig. 2F shows, at baseline the platelet
count in PAD4−/− mice was normal. Platelets isolated from
PAD4−/− mice aggregated normally in response to low and high
doses of thrombin (Fig. 3 D and E). This shows that, in general,
platelet activation, granule secretion, and integrin activation are
not affected in these mice. We then examined in vivo models in
which platelets respond to injury by forming a platelet plug: tail
bleeding time and the ferric chloride model of thrombosis. Tail-
tip transection results in severing of both veins and artery, and
the rapid cessation of blood ﬂow depends on platelet function
and coagulation. Time to cessation of bleeding was similar in
WT and PAD4−/− mice (Fig. 3F), indicating that these mice have
normal hemostatic potential. In the venous stenosis model, ﬂow
restriction leads to WPB secretion potentially due to local
hypoxia (25), resulting in platelet–leukocyte interactions with the
Fig. 1. PAD4 is necessary for NET formation in response to Ca2+ ionophore
and LPS from K. pneumoniae. (A and B) Neutrophils isolated from WT and
PAD4+/− mice became hypercitrullinated at histone H3 (A) and formed NETs
(B) in response to stimulation with LPS or ionomycin for 2 h. Stimulated
PAD4−/− neutrophils were negatively stained by an antibody recognizing
histone H3 citrullination at residues 2, 8, and 17 and did not form NETs. (C)
Representative micrographs of ionomycin-stimulated cells showing an H3Cit-
positive NET emerging from a WT neutrophil and a condensed, delobulated
nucleus in a PAD4−/− neutrophil. H3Cit staining was absent in PAD4−/−
neutrophils. H3Cit, green; Gr1 antigen on plasma membrane, orange; DNA,
blue. Representative of n = 4. (Scale bar, 10 μm.) *P < 0.05.











endothelium. In the ferric chloride model, by contrast, oxida-
tive injury removes the endothelium and exposes circulating
blood to the subendothelial matrix (26). Platelets bind to the
subendothelium via glycoprotein Ib (GPIb), integrins, and gly-
coprotein VI (GPVI) and then become activated and aggregate
via integrin receptors (27). We visualized thrombus formation in
FeCl3-injured mesenteric venules using intravital microscopy and
found that PAD4−/− mice formed occlusive thrombi with similar
kinetics (Fig. 3G) and thrombus morphologies (Fig. 3H) as WT
mice. Thus, we have no evidence that PAD4 or NETs play a sig-
niﬁcant role in hemostasis in healthy mice. For platelet plug
formation in the injured veins, coagulation is likely driven by
vessel wall tissue factor. Here the enhancement of coagulation
and thrombosis by NETs may not be necessary.
Neutrophil PAD4 Is a Key Player in Pathological Thrombus Formation.
To assess whether the inﬂuence of PAD4 was of hematopoietic
origin, we generated bone marrow (BM) chimeras by infusing
WT or PAD4−/− BM cells into lethally irradiated WT recipients.
Both groups of mice recovered body mass with similar kinetics
(Fig. S2A). To test the chimerism, we stimulated leukocytes
from whole blood after red blood cell (RBC) lysis with ion-
omycin and found that the PAD4−/− BM chimeras failed to
hypercitrullinate arginine residues at histone H3 (Fig. S2 B and
C). Similar to the thrombus formation frequencies in WT and
PAD4−/− mice, a majority (six of seven) of WT BM chimeras
produced thrombi after 48 h of stenosis, whereas only one of
the seven PAD4−/− BM chimeras formed a small thrombus
(Fig. 4 A and B). The H3Cit pattern within thrombi paralleled the
results seen in WT and PAD4−/− mice, with extracellular H3Cit
present in the thrombi of WT BM chimeras but H3Cit staining
absent in the PAD4−/− BM chimera thrombus (Fig. S2 D and E).
WT BM chimeras became thrombocytopenic 48 h poststenosis,







Fig. 2. PAD4−/− mice are protected from DVT, especially at 48 h after stenosis. (A and B) PAD4−/− mice were less likely to form thrombi at 6 h than WT mice.
(C) Platelet count is decreased in WT compared with PAD4−/− mice after 6 h in the venous stenosis model. (D and E) At 48 h, only one small thrombus was
present in a PAD4−/− mouse, whereas all but one of the WT mice had thrombi. (F) WT and PAD4−/− mice have similar platelet counts before stenosis
(“Baseline”). WT mice are thrombocytopenic at 48 h, whereas platelet counts remain stable in PAD4−/−mice. (G and H) Composite image of a section from an
entire thrombus collected at 48 h showing diffuse, extracellular H3Cit (green) staining in a WT mouse (G), which is completely absent in the sole thrombus
from a PAD4−/−mouse (H). Hoechst staining of DNA is shown in blue and shows extensive presence of leukocytes in both thrombi. (Scale bars, 100 μm.) (I) H&E
staining of 48 h thrombi shows less dense nuclear staining and diffuse, likely extracellular, DNA (arrows) in WT thrombi compared with dense nuclei found in
the PAD4−/− thrombus. (Scale bar, 20 μm.) (J) Thrombi collected from WT mice or the PAD4−/− mouse that formed a thrombus 48 h after IVC stenosis showed
an abundance of neutrophils by Ly6G immunostaining (red). (Scale bar, 20 μm.) DNA is shown in blue. *P < 0.05, **P < 0.01, ***P < 0.001.
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As PAD4 is expressed by other leukocytes in addition to neu-
trophils (28, 29) that may enter the thrombus, we investigated
whether the infusion of WT neutrophils could rescue thrombosis
in PAD4−/− mice at 48 h. Infusing 4–5 × 106 isolated WT BM
neutrophils into PAD4−/− mice restored thrombus generation
(Fig. 4 D and E). Although a signiﬁcant lowering of platelet count
was not achieved by neutrophil infusion (Fig. 4F), mice that had
formed a thrombus in either WT and PAD4−/− recipients did,
however, have a signiﬁcant decrease in platelet count compared
with baseline levels (Fig. S3). Infused neutrophils were of >95%
purity as assessed by Wright–Giemsa staining (Fig. S4C). The
thrombi from neutrophil-infused PAD4−/− mice contained large
numbers of Ly6G+ neutrophils, whereas F4/80+ monocytes/
macrophages were rarely seen within all thrombi examined
(Fig. S4 A, B, and D). Thrombi were analyzed by immunoﬂu-
orescence, and extracellular H3Cit staining was present within
both WT and PAD4−/− recipient thrombi after WT neutrophil
infusion (Fig. 4 G and H), indicating that the WT neutrophils
were incorporated and produced NETs in the thrombus scaffold
in PAD4−/− recipient mice. Therefore, PAD4 within neutrophils
is important for formation of stable thrombi in large veins, as the
defect in thrombosis in PAD4−/− mice can be rescued by supple-
mentation with WT neutrophils.
Discussion
For more than 150 y, the conditions of hypercoagulable state,
hypoxia due to ﬂow disturbance such as in valves or stasis, and
vascular activation were recognized as the main players in DVT
(30). Only recently has the active contribution of blood cells
to DVT begun to be appreciated. First, the complex role of
inﬂammatory cells was recognized in that they promote throm-
bosis, for example, through production of tissue factor, and also
contribute to thrombus resolution (31). Second, the important role
of platelets in DVT has been described in animal models and hu-
man trials (9, 32, 33). Venous pathological thrombi were thought
to be formed by ﬁbrin and trapped RBCs, and the main treatment
in humans is still anticoagulation. It is now clear that pathological
thrombus formation and stabilization are much more complex,
with many platelets and leukocytes present, and even the RBCs
may not be trapped but rather actively recruited to the thrombus by
NETs (6). Thus, new treatment options are being revealed.
Here we reveal a different facet of DVT—the importance of
neutrophil posttranslational modiﬁcation and chromatin decon-
densation, factors dramatically inﬂuencing outcome of stenosis-
induced DVT in mice. The enzyme PAD4 allows for dissociation
of heterochromatin protein 1-β (19), affects linker histone H1
(16), and reduces the positive charge of histones by arginine cit-
rullination, thus allowing nucleosomes to unravel and chromatin
to be expelled from the swollen nuclei. Absence of NETosis
resulted in the formation of fewer thrombi in PAD4−/− mice early
after the ﬂow disturbance/hypoxia onset with almost no thrombi
by 48 h. Here we describe DVT as a noninfectious model in which
the PAD4−/− mice are affected, and, surprisingly, to date this is
the strongest phenotype described in these mice (18, 34, 35).
We have demonstrated that PAD4 deﬁciency does not perturb
initial vessel wall activation and platelet–leukocyte adhesion.
Also, platelets from PAD4 knockout mice are fully functional
and able to produce platelet plugs like WT platelets. The low
incidence of DVT in PAD4−/− mice is largely caused by a lack of






Fig. 3. Normal adhesive interactions among pla-
telets, leukocytes, and endothelium in PAD4−/−
mice. (A) Representative images of platelets, leu-
kocytes, and platelet–leukocyte aggregates on en-
dothelium in WT (Left) or PAD4−/− (Right) IVCs
collected 6 h after ligation. VWF, red; CD41 (plate-
lets), green; DNA, blue. n = 3–4. (Scale bar, 20 μm.)
(B and C) Activated platelets were infused into WT
or PAD4−/−mice. (B) Leukocyte rolling was assessed
in mesenteric venules by counting the number of
cells crossing a deﬁned line per minute. Baseline
leukocyte rolling was determined in untreated
mice. n = 4–6. (C) Representative still images from
intravital microscopy movies showing numerous
rolling leukocytes 2 h after activated platelet in-
fusion in WT or PAD4−/− mice. (Scale bar, 100 μm.)
(D and E) Aggregometry of washed platelets stim-
ulated with thrombin at 1 or 0.01 U/mL. (D) Maxi-
mum aggregation was similar between WT and
PAD4−/− mice. (E) Representative traces showing
similar kinetics of aggregation between platelets
fromWT and PAD4−/−mice. Red line, PAD4−/−; black
line, WT. n = 4–5. (F) A 2-mm tail segment was
transected and bleeding was monitored for 15
min. The time to the ﬁrst cessation in bleeding
was recorded for each mouse. One mouse from
each group failed to stop bleeding, and these
mice were determined to be statistical outliers
using Grubb’s test and excluded from means. (G
and H) Venous thrombosis after injury. Mesen-
teric venules were externalized and injured with
application of 10% FeCl3-soaked ﬁlter paper for
5 min. (G) Time to vessel occlusion was measured
and found to be similar in WT and PAD4−/− mice.
(H) Representative images of occlusive thrombi
formed in WT (Left) or PAD4−/− mice (Right). n =
11–12. (Scale bar, 200 μm.)











process. The protection in PAD4−/−mice from DVT is due to the
failure of neutrophils to form NETs as the PAD4−/− neutrophils
interact properly with the vessel wall and are present in the rare
thrombi that form in PAD4−/− veins. Our observation of less
extracellular H3Cit in WT thrombi at 6 h than at 48 h (Fig. S1
and Fig. 2) ﬁts well with the report of von Brühl and colleagues
(10) showing that neutrophils begin to throw NETs by 3 h in this
DVT model, but the prominent diffuse staining pattern of NETs
is present only later, at 48 h. Thus, NETs compose a crucial part
of the pathologic thrombus scaffold, and the lack of NET for-
mation results in fewer thrombi early on that appear not to be
sustained over time.
Our observations help to pinpoint the importance of neutrophils
and NETs in thromboembolic disease. Inhibitors of neutrophil
activation in the thrombus, inhibitors of PAD4 activation, or
inhibitors of NET release would all impact DVT outcome.
Therapeutic interventions combining both DNases and pro-
teolytic enzymesmay improve thrombolysis in patients withDVT. In
addition, speciﬁc PAD4 inhibitors are not likely to impair hemostasis
or neutrophil function in thrombus resolution. Thus, a better un-
derstanding of the complexity of pathological thrombosis, including
the process of chromatin decondensation in neutrophils, will bring us
closer to devising more effective and targeted treatments.
Materials and Methods
Mice. Experimental procedures in this study were reviewed and approved by
the Institutional Animal Care and Use Committee of Boston Children’s
Hospital (protocol nos. 11–03-1919, 11–04-1848, 11–03-1941). WT mice were
purchased from Jackson Laboratory. PAD4−/− mice have been recently
backcrossed to C57BL/6J for seven or more generations.
Neutrophil Isolation for in Vitro NET Assays. Peripheral blood was collected via
the retroorbital venous plexus, and neutrophils were isolated from 6- to
10-wk-old male or female WT, PAD4+/−, or PAD4−/− mice as previously de-
scribed (11). Cells were routinely assessed to be >90% pure by Wright–
Giemsa stain. Neutrophils in RPMI/Hepes were allowed to adhere at 37 °C in
5% CO2 to glass-bottom plates for 20 min before stimulation with 10 μg/mL
LPS from K. pneumoniae (Sigma) or 4 μM ionomycin (Invitrogen). After 2 h,
cells were ﬁxed in 2% (vol/vol) paraformaldehyde.
Venous Stenosis Model. Venous stenosis experiments were performed as
previously described (8). Please see Supporting Information for more de-
tailed methods.
Immunostaining and Fluorescence Microscopy. Fixed cells or tissue sections
were washed with PBS and permeabilized (0.1% Triton X-100, 0.1% sodium
citrate) for 10 min at 4 °C. Samples were blocked with 3% (wt/vol) BSA for 90
min at 37 °C, rinsed, and then incubated overnight at 4 °C or for 1 h at 37 °C
in antibody dilution buffer containing 0.3% BSA, 0.1% Tween-20, and either
rabbit antihistone H3 (citrulline 2, 8, 17) (0.3 μg/mL, ab5103; Abcam), rat anti-
Gr1 (0.5 μg/mL, clone RB6-8C5; eBioscience), rat anti-Ly6G (0.5 μg/mL, clone
1A8; Biolegend), or rat anti-F4/80 (1:250, ab16911; Abcam). After several
washes, samples were incubated for 2 h at room temperature in antibody
dilution buffer containing Alexa Fluor-conjugated secondary antibodies in
0.3% BSA in PBS: goat anti-rat Ig (IgG) (Alexa555, 2 μg/mL), donkey anti-rabbit
IgG (Alexa488, 1.5 μg/mL), or donkey anti-sheep IgG (Alexa568, 2 μg/mL;
Invitrogen). DNA was counterstained with 1 μg/mL Hoechst 33342 and slides
were coverslipped with Fluoromount gel (Electron Microscopy Sciences).
Fluorescent images were acquired using an Axiovert 200 wideﬁeld ﬂuores-
cence microscope (Zeiss) in conjunction with an AxiocamMRmmonochromatic
CCD camera (Zeiss) and analyzed with Zeiss Axiovision software. All channels
were acquired in grayscale and pseudocolored using Zeiss Axiovision or ImageJ




Fig. 4. Venous thrombosis depends on the presence of PAD4 in neutrophils. (A–C) Chimeric mice were generated by infusing WT or PAD4−/− BM cells into
lethally irradiatedWT recipients and later subjected to 48 h of IVC stenosis. (A) Percentage of BM chimeras that produced thrombi. (B) Length of thrombi. (C)
Platelet counts in BM chimeras 48 h after DVT surgery. WT→WT BM chimeras became thrombocytopenic, whereas PAD4−/−→WT BM chimeras maintained
normal platelet counts. (D–H) WT or PAD4−/− mice received an i.v. infusion of 4–5 × 106 WT neutrophils immediately before DVT surgery and 2–2.5 × 106
neutrophils at 24 h. (D and E ) A majority (80%) of both WT and PAD4−/−mice formed thrombi after the infusion of WT neutrophils. (F) Similar platelet counts
were measured 48 h after IVC ligation inWT and PAD4−/−mice infusedwithWT neutrophils. (G andH) Composite images of thrombi collected frommice infused
withWT neutrophils. H3Cit-positive nuclei and extracellular staining was detected inWT (G) and PAD4−/− (H) thrombi, indicating that the infusedWT neutrophils
integrated into the PAD4−/− thrombus. H3Cit, green; DNA, blue. Representative of n = 4. (Scale bar, 100 μm.) *P < 0.05.
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WT and PAD4−/− thrombi or neutrophils. Composite images were generated
with the MosaicJ plugin (36) for ImageJ software.
Platelet Counts. Whole blood was collected via the retroorbital sinus into
EDTA-coated capillary tubes. Twenty-ﬁve μL of blood was analyzed by a
Hemavet 950FS (Drew Scientiﬁc) for complete blood counts.
Platelet Aggregation. Murine blood was collected in 10% (vol/vol) sodium
citrate [3.2% (wt/vol)] and centrifuged at 800 × g for 10 min. Platelet-rich
plasma was collected, and supplemented with prostacyclin in Tyrode’s
buffer. Platelets were washed and resuspended in Tyrode’s buffer and in-
cubated at 37 °C. Platelets (2.5 × 105/μL) were analyzed using a Chronolog
Platelet aggregometer. Thrombin (1 or 0.01 U/mL) in the presence of calcium
chloride was used as an agonist for aggregation, and samples were analyzed
for at least 10 min.
Tail Bleeding Time. Six- to 8-wk-old male or female C57BL/6J or PAD4−/− mice
were anesthetized using 2.5% (vol/vol) tribromoethanol (300 mg/kg)
administered intraperitoneally. A 2-mm segment of the tail tip was trans-
ected using a single-edge razor blade, and the tail was immediately sub-
mersed in 37 °C PBS. Tail bleeding was monitored for 15 min, and the time to
stop was recorded when bleeding had stopped for more than 30 s. All mice
were euthanized immediately at the end of the observation period.
FeCl3-Induced Mesenteric Venous Thrombosis. Three- to 4-wk-old C57BL/6J or
PAD4−/− male mice were anesthetized using 2.5% (vol/vol) tribromoethanol
(300 mg/kg) administered i.p., and the level of anesthesia was veriﬁed by
lack of response to footpad squeeze. Rhodamine 6G was given via retro-
orbital injection to ﬂuorescently label platelets and leukocytes. A midline
incision was performed, and the intestines externalized to reveal mesenteric
vessels. A single venule of between 200 to 300 μm in diameter was visualized
for each mouse (WT mice, 222.2 ± 20.6 μm; PAD4−/− mice, 239.0 ± 44.6 μm).
A 1- × 3-mm piece of ﬁlter paper was soaked in 10% ferric chloride, gently
placed on the vessel for 5 min, and then removed. Occlusion time was noted
for each mouse. Vessels were considered occluded when blood ﬂow had
stopped for at least 10 s.
Bone Marrow Chimera Preparation. Four-week-old C57BL/6J males were le-
thally irradiated with 1,100 rad and immediately given an i.v. injection of at
least 1 × 107 bone marrow cells from either WT or PAD4−/− mice. See Sup-
porting Information for detailed methods.
Neutrophil Infusion. Neutrophil adoptive transfer studies were performed as
previously described (37). BM neutrophils were isolated from 6- to 8-wk-old
C57BL/6J WT mice using a Percoll (GE Healthcare Life Sciences) gradient and
rapid hypotonic lysis. Bone marrow was ﬂushed out of tibias and femurs
using a 30-G needle into cold RPMI. Cells were pelleted, resuspended in PBS,
and layered onto a Percoll gradient containing 78%/69%/52% (vol/vol)
Percoll. Cells at the 78%/69% interface were collected and subjected to
hypotonic lysis. Cells were counted using a hemacytometer and resuspended
in RPMI. Purity was assessed by Wright–Giemsa staining, which was de-
termined to be >95% neutrophils. Cells (4–5 × 106) were injected i.v. through
the retroorbital sinus immediately before DVT surgery. A second i.v. neu-
trophil infusion of 2–2.5 × 106 neutrophils was given at 24 h. Mice were
euthanized at 48 h, and any resulting thrombi were harvested for analysis.
Statistics. Data are presented asmeans± SEM unless otherwise noted andwere
analyzed using a two-sided Student t test or Mann–Whitney U test. Thrombus
frequencies were analyzed using χ2 tests of contingency tables. All analyses
were performed using GraphPad Prism software (Version 5.0). Results were
considered signiﬁcant at P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001).
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